{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-26-000129","form_type":"8-K","ticker":"IMUX","cik":"0001280776","company_name":"IMMUNIC, INC.","filed_at":"2026-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.695558+00:00","generated_at":"2026-05-16T02:46:17.486303+00:00","sec_items":["1.01","3.02","8.01","5.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Immunic announces up to $400M private placement and board changes to fund MS trials","bullets":["Gross proceeds of up to $400M from private placement led by BVF Partners, with $200M from pre-funded warrants at $0.873 each.","Proceeds to fund completion of Phase 3 ENSURE trials in relapsing MS and initiation of Phase 3 in primary progressive MS.","Simona Skerjanec appointed interim chair; Thor Nagel joins board; Maria Törnsén resigns.","Company entered into royalty purchase agreement with Series B warrant holders for 5% synthetic royalty on vidofludimus calcium sales.","Company plans to search for new CEO with commercial experience; Dr. Vitt to transition to senior scientific role."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-26-000129","json":"https://secwatch.observer/filing/0001193805-26-000129.json","markdown":"https://secwatch.observer/filing/0001193805-26-000129.md","text":"https://secwatch.observer/filing/0001193805-26-000129.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000129/0001193805-26-000129-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000129/e665154_8k-immunic.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-16T02:46:17.486303+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"68092fd6aaecee61e10fc93e22e3dd4632d2a032","claim":"IMMUNIC, INC. entered into Securities Purchase Agreement with certain accredited investors valued at approximately $200 million (effective 2026-02-12).","evidence_excerpt":"On February 12, 2026, Immunic Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain accredited investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell, in a private placement (the “ Offering ”), pre-funded warrants","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000129/0001193805-26-000129-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain accredited investors"},{"label":"Value","value":"approximately $200 million"},{"label":"Effective","value":"2026-02-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}